12月30日，聚光科技盘中下跌2.05%，截至09:54，报15.76元/股，成交4173.98万元，换手率0.59%，总 市值70.72亿元。 聚光科技所属申万行业为：环保-环保设备Ⅱ-环保设备Ⅲ。所属概念板块包括：PM2.5、传感器、融资 融券、增持回购、土壤修复等。 截至9月30日，聚光科技股东户数2.30万，较上期增加13.30%；人均流通股19483股，较上期减少 11.74%。2025年1月-9月，聚光科技实现营业收入20.50亿元，同比减少11.10%；归母净利润-6233.51万 元，同比减少152.98%。 分红方面，聚光科技A股上市后累计派现6.30亿元。近三年，累计派现1.12亿元。 机构持仓方面，截止2025年9月30日，聚光科技十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1381.53万股，相比上期减少518.92万股。睿远成长价值混合A（007119）位居第五大流通 股东，持股1085.88万股，相比上期增加242.09万股。诺安先锋混合A（320003）、汇添富医药保健混合 （470006）退出十大流通股东之列。 责任编辑：小浪快报 资金流向方面，主力资金净流出 ...

Core Viewpoint - The stock of 聚光科技 (Juguang Technology) has shown a mixed performance in recent trading sessions, with a slight increase in price but a significant decline in revenue and profit year-on-year [1][2]. Group 1: Stock Performance - On December 19, 聚光科技's stock rose by 2.06%, reaching a price of 15.87 yuan per share, with a trading volume of 33.57 million yuan and a turnover rate of 0.48% [1]. - Year-to-date, the stock price has increased by 5.94%, with a 0.44% rise over the last five trading days, a 7.96% increase over the last 20 days, but a 16.21% decline over the last 60 days [1]. - The company has appeared on the龙虎榜 (top trading list) once this year, with the most recent occurrence on April 9 [1]. Group 2: Financial Performance - For the period from January to September 2025, 聚光科技 reported a revenue of 2.05 billion yuan, reflecting a year-on-year decrease of 11.10%, and a net profit attributable to shareholders of -62.34 million yuan, a significant decline of 152.98% [2]. - Cumulatively, the company has distributed 630 million yuan in dividends since its A-share listing, with 112 million yuan distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for 聚光科技 increased to 23,000, a rise of 13.30%, while the average number of circulating shares per person decreased by 11.74% to 19,483 shares [2]. - Among the top ten circulating shareholders, 香港中央结算有限公司 (Hong Kong Central Clearing Limited) holds 13.82 million shares, a decrease of 5.19 million shares from the previous period, while 睿远成长价值混合A (Ruiyuan Growth Value Mixed A) increased its holdings by 2.42 million shares to 10.86 million shares [3].

Financial Data and Key Metrics Changes - The company experienced an uplift of approximately $60 million from Q3 to Q4, driven by three primary factors including a significant increase in the Genomics England contract from $2 million in Q3 to $7 million in Q4 [1][2][52] - The foreign exchange (FX) impact was less favorable than predicted, resulting in a drag of $5-$7 million on absolute dollar amounts, which is 1% less than expected [3][52] Business Line Data and Key Metrics Changes - The life sciences instrumentation side showed continued good activity, with trends remaining stable compared to previous months [2] - The reagents business, particularly from BioLegend, faced modest impacts from government shutdowns, while the pharma biotech sector showed signs of recovery [5][10] - The software segment has grown over 20% each quarter this year, significantly exceeding initial guidance of 10% [20][21] Market Data and Key Metrics Changes - The U.S. market for immunodiagnostics has grown from 5% to 15-20% of total EUROIMMUN revenue since acquisition, with expectations to reach 40-45% as more assays are introduced [38][39] - The China market remains crucial, with expectations for diagnostics to stabilize around 5-6% of company revenue, while life sciences in China is projected to be around 10-12% [44][45] Company Strategy and Development Direction - The company aims to leverage AI and machine learning across its product lines, focusing on enhancing drug discovery and development processes [22][35] - Strategic acquisitions will continue, with a focus on sensible and financially sound opportunities, as demonstrated by the recent acquisition of ACD/Labs [58] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in the pharma biotech sector, indicating that increased M&A activity would signal normalization in the market [7][8][16] - The company anticipates stable growth in 2026, projecting 2-3% growth with 28% margins, accounting for various market dynamics [56][57] Other Important Information - The company has been proactive in addressing challenges in the China market, focusing on innovation and local competition strategies [43][44] - The newborn screening segment has shown growth driven by geographic expansion and partnerships with local governments [48][49] Q&A Session Summary Question: Can you discuss the life sciences diagnostics and the impact of government shutdowns? - The reagents business saw modest impacts from shutdowns, but the pharma biotech sector is recovering, indicating a return to normalcy [5][10] Question: What are the expectations for the software business moving forward? - The software segment is expected to continue its strong growth trajectory, with a focus on annualized portfolio value as a key metric [27][29] Question: How does the company view the China diagnostics market? - The company acknowledges the challenges in China but remains focused on innovation and local market strategies to stabilize and grow [42][44]

Financial Data and Key Metrics Changes - The company experienced an uplift of approximately $60 million from Q3 to Q4, driven by three primary factors including the Genomics England contract which contributed around $7 million in Q4 compared to $2 million in Q3 [1][2] - The foreign exchange (FX) impact was a drag of $5-$7 million, which is 1% less than previously predicted, affecting absolute dollar amounts but having minimal impact on growth and earnings per share (EPS) [3] Business Line Data and Key Metrics Changes - The life sciences instrumentation side has shown good activity, with seasonal uplift expected rather than a significant budget flush [2][12] - The reagents business, particularly from BioLegend, faced modest impacts from government shutdowns, but the pharma biotech sector has shown signs of recovery [5][8] - The software segment has grown over 20% each quarter, significantly exceeding guidance, driven by diligent investment and customer engagement [19][21] Market Data and Key Metrics Changes - The U.S. market for EUROIMMUN has increased from 5% to 15-20% of total revenue since acquisition, with expectations to reach 40-45% as more assays are introduced [36] - The China diagnostics market is projected to stabilize, with expectations of it contributing 5-6% to total revenue, while autoimmune testing is anticipated to grow significantly [43][44] Company Strategy and Development Direction - The company is focusing on leveraging AI and machine learning in drug discovery and development, positioning itself as a critical player in the future of pharmaceutical research [22][31] - Strategic acquisitions will continue, with a focus on sensible and financially sound opportunities, as demonstrated by the recent acquisition of ACD/Labs [57] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in the pharma biotech sector, indicating that increased discussions and activity are signs of normalization [15][16] - The company is confident in its 2026 growth projections of 2-3% and 28% margins, accounting for stable market conditions and the impact of calendarization on China [54][56] Other Important Information - The company has been actively integrating AI across its product lines and internal operations, enhancing productivity and efficiency [34][35] - The newborn screening market has shown growth due to geographic expansion and the introduction of new assays, with partnerships driving further opportunities [46][48] Q&A Session Summary Question: Can you discuss the impact of the government shutdown on the reagents business? - The reagents business, particularly from BioLegend, experienced a modest impact from the shutdown, but the pharma biotech sector has continued to perform well [5][8] Question: What are the expectations for the software business moving into 2026? - The software business is expected to continue performing well, with a focus on annualized portfolio value (APV) rather than just organic growth [27][28] Question: How does the company view the China diagnostics market going forward? - The company anticipates that the China diagnostics market will stabilize, contributing around 5-6% to total revenue, with a focus on localizing operations and obtaining faster approvals [43][44]

特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无 法看到我们的推送。 仪粉er们，今天是精品仪器销售、售前类职位专辑 哦！ 仪器精英，热招职位 Ho t r e c r u itme n t p o siti o n s 销售类 九圃 营销副总 上海-30k-35k ·14薪 任职要求： 本科及以上学历，农学、生物学、营销学等相关专业；10年以上实验室仪器设备 行业销售管理经验，成功主导过大项目，具备外企高管经验优先考虑；具备较好的销售渠道资 源及行业客户资源；精通营销策略分析、销售团队建设、市场推广技巧；具备谈判和危机处理 能力；适应出差。 上海凯来 仪器销售工程师（地质学/材料学方向） 上海-15k-25k ·12薪 任职要求： 化学、地质学、材料学等相关专业，本科及以上学历；熟悉ICP-MS技术和市场， 五年以上仪器销售经验；熟悉科研类、军工类和材料类用户的市场特点，能适应出差。 海能未来 销售工程师（科学仪器） 北京-10k-15k ·12薪 任职要求： 本科及以上学历，制药、食品、化学、环境等相关专业优先，有科学仪器产品营销 经验者优先；具备 ...

Core Viewpoint - Wante Bio's stock has experienced a significant decline in 2023, with a year-to-date drop of 31.73% and a recent 60-day decline of 17.40% [2] Company Overview - Wante Bio, established on April 24, 1991, and listed on April 29, 2020, is located in Changping District, Beijing. The company specializes in the research, production, and sales of in vitro diagnostic reagents, instruments, and vaccines [2] - The revenue composition of Wante Bio includes: diagnostic reagents (67.06%), vaccines (20.36%), diagnostic instruments (4.98%), agency products (4.97%), other (1.88%), and active raw materials (0.76%) [2] - As of September 30, 2025, Wante Bio had 42,000 shareholders, an increase of 9.41% from the previous period, with an average of 30,124 circulating shares per shareholder, a decrease of 8.60% [2] Financial Performance - For the period from January to September 2025, Wante Bio reported a revenue of 1.498 billion yuan, a year-on-year decrease of 23.09%, and a net profit attributable to shareholders of -173 million yuan, a year-on-year decrease of 165.04% [2] - Since its A-share listing, Wante Bio has distributed a total of 1.541 billion yuan in dividends, with 1.311 billion yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders of Wante Bio include Hong Kong Central Clearing Limited, which holds 12.8991 million shares (a decrease of 9.8553 million shares), and Huatai-PB CSI 300 ETF, holding 6.4061 million shares (a decrease of 318,300 shares) [3] - The China National Securities Bio-Medical Index A has entered the top ten circulating shareholders with 4.9609 million shares as a new shareholder, while E Fund CSI 300 Medical ETF has exited the list [3] Market Activity - On November 28, Wante Bio's stock price fell by 2.02%, trading at 48.10 yuan per share, with a total transaction volume of 131 million yuan and a turnover rate of 0.21%. The total market capitalization is 60.852 billion yuan [1] - In terms of capital flow, there was a net outflow of 17.3687 million yuan from main funds, with large orders showing a buy of 23.094 million yuan (17.66%) and a sell of 27.222 million yuan (20.82%) [1]

Core Viewpoint - The stock of 聚光科技 (Juguang Technology) has experienced fluctuations, with a recent decline of 2.06% and a total market capitalization of 6.825 billion yuan. The company has faced a decrease in revenue and profit in the first nine months of 2025 compared to the previous year [1][2]. Financial Performance - As of September 30, 2025, 聚光科技 reported a revenue of 2.05 billion yuan, a year-on-year decrease of 11.10% [2]. - The net profit attributable to shareholders was -62.34 million yuan, representing a significant year-on-year decrease of 152.98% [2]. - The company has cumulatively distributed 630 million yuan in dividends since its A-share listing, with 112 million yuan distributed in the last three years [3]. Stock Market Activity - On November 28, 2025, 聚光科技's stock price was 15.21 yuan per share, with a trading volume of 51.77 million yuan and a turnover rate of 0.75% [1]. - The stock has increased by 1.54% year-to-date, but has seen a decline of 8.37% over the past 20 days and 28.12% over the past 60 days [1]. - The company has appeared on the龙虎榜 (top trading list) once this year, with the last occurrence on April 9 [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 13.30% to 23,000, while the average number of circulating shares per person decreased by 11.74% to 19,483 shares [2]. - The top three circulating shareholders include Hong Kong Central Clearing Limited, which reduced its holdings by 5.19 million shares, and 睿远成长价值混合A, which increased its holdings by 2.42 million shares [3].

Core Viewpoint - The stock of 聚光科技 (Juguang Technology) has shown fluctuations in recent trading sessions, with a current market value of 6.969 billion yuan and a year-to-date price increase of 3.67% despite a significant decline over the past two months [1][2]. Financial Performance - For the period from January to September 2025, 聚光科技 reported a revenue of 2.05 billion yuan, representing a year-on-year decrease of 11.10% [2]. - The company experienced a net loss attributable to shareholders of 62.34 million yuan, a substantial decline of 152.98% compared to the previous year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 23,000, up by 13.30% from the previous period, while the average number of circulating shares per person decreased by 11.74% to 19,483 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 13.82 million shares, a decrease of 5.19 million shares from the previous period [3]. Dividend Distribution - Since its A-share listing, 聚光科技 has distributed a total of 630 million yuan in dividends, with 112 million yuan distributed over the last three years [3]. Business Overview - 聚光科技, established on January 4, 2002, and listed on April 15, 2011, specializes in the research, production, and sales of instruments and equipment for environmental monitoring, industrial process analysis, and laboratory instruments [1]. - The company's revenue composition includes 69.24% from instruments, software, and consumables, 16.42% from operational and consulting services, 10.46% from environmental equipment and engineering, and 3.87% from other sources [1].

Core Viewpoint - The stock of 聚光科技 (Juguang Technology) has experienced a decline in recent trading sessions, with a current market value of 6.92 billion yuan and a year-to-date price increase of only 2.94% [1][2]. Financial Performance - For the period from January to September 2025, 聚光科技 reported a revenue of 2.05 billion yuan, representing a year-on-year decrease of 11.10%. The net profit attributable to shareholders was -62.34 million yuan, a significant decline of 152.98% compared to the previous year [2]. - The company has distributed a total of 630 million yuan in dividends since its A-share listing, with 112 million yuan distributed over the last three years [3]. Stock Market Activity - As of November 18, the stock price of 聚光科技 was 15.42 yuan per share, with a trading volume of 81.96 million yuan and a turnover rate of 1.18%. The stock has seen a decline of 4.87% over the last five trading days and 25.25% over the last 60 days [1]. - The company has appeared on the龙虎榜 (top trading list) once this year, with the last occurrence on April 9 [1]. Shareholder Information - As of September 30, 2025, the number of shareholders for 聚光科技 increased by 13.30% to 23,000, while the average number of circulating shares per person decreased by 11.74% to 19,483 shares [2]. - The top three circulating shareholders include Hong Kong Central Clearing Limited, which holds 13.82 million shares (a decrease of 5.19 million shares), and 睿远成长价值混合A (Ruiyuan Growth Value Mixed A), which increased its holdings by 2.42 million shares to 10.86 million shares [3].

Core Insights - On November 17, 2023, 聚光科技's stock increased by 0.06% with a trading volume of 58.45 million yuan [1] - The company reported a financing buy-in of 8.30 million yuan and a net financing buy of 0.65 million yuan on the same day [1] - As of November 17, the total financing and securities lending balance for 聚光科技 was 445 million yuan, representing 6.29% of its market capitalization [1] Financing Overview - On November 17, 聚光科技 had a financing buy-in of 8.30 million yuan, with a current financing balance of 445 million yuan, which is above the 50th percentile level for the past year [1] - The company had a securities lending activity where 300 shares were repaid and 400 shares were sold, with a total selling amount of 6,296 yuan [1] - The securities lending balance was 617,000 yuan, which is below the 50th percentile level for the past year [1] Company Performance - As of September 30, 2023, 聚光科技 had 23,000 shareholders, an increase of 13.30% from the previous period [2] - The average number of circulating shares per shareholder decreased by 11.74% to 19,483 shares [2] - For the period from January to September 2023, the company reported a revenue of 2.05 billion yuan, a year-on-year decrease of 11.10%, and a net profit attributable to shareholders of -62.34 million yuan, a decrease of 152.98% [2] Dividend and Shareholding Structure - Since its A-share listing, 聚光科技 has distributed a total of 630 million yuan in dividends, with 112 million yuan distributed over the past three years [3] - As of September 30, 2023, the third-largest circulating shareholder was Hong Kong Central Clearing Limited, holding 13.82 million shares, a decrease of 5.19 million shares from the previous period [3] - The fifth-largest circulating shareholder, Ruiyuan Growth Value Mixed A, increased its holdings by 2.42 million shares to 10.86 million shares [3]